Skip to main content

Day: September 6, 2022

IO Biotech to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today that Mai-Britt Zocca, the company’s President and CEO, will be participating in a fireside chat and investor meetings at the Morgan Stanley 20th Annual Global Healthcare Conference, taking place September 12 – 14, 2022. Fireside Chat DetailsDate and Time: Wednesday, September 14, 2022 at 8:35 a.m. ETPresenter: Mai-Britt Zocca, President & CEOWebcast Link: Here A webcast replay of the presentation will be available from the Investors section of the Company’s website at www.iobiotech.com for 180 days. About IO Biotech IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating...

Continue reading

Arbutus to Participate in September Investor Conferences

WARMINSTER, Pa., Sept. 06, 2022 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in the following upcoming investor conferences taking place in New York: H.C. Wainwright 24th Annual Global Investment Conference (September 12-14, 2022)Company Presentation: Tuesday, September 13th at 12:30 pm ET Presenter: William Collier, President & Chief Executive OfficerBaird’s 2022 Global Healthcare Conference (September 13-14, 2022)Fireside Chat: Wednesday, September 14th at 10:15 am ET Presenters: William Collier, President & Chief Executive Officer; Dr. Gaston Picchio, Chief Development Officer; Michael McElhaugh,...

Continue reading

Ikena Oncology to Participate in September 2022 Investor Conferences

BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in two upcoming investor conferences in New York, NY. Management will be participating in investor meetings at the H.C. Wainwright 24th Annual Global Investment Conference and at the Morgan Stanley 20th Annual Global Healthcare Conference, where Mark Manfredi, Ph.D., Chief Executive Officer of Ikena, will also be conducting a fireside chat. Details are as follows: H.C. Wainwright 24th Annual Global Investment ConferenceInvestor Meetings September 12-14, 2022 Morgan Stanley 20th Annual Global Healthcare ConferenceInvestor Meetings September 12-14, 2022Fireside Chat: Wednesday, September 14, 2022 at 11:45 a.m....

Continue reading

OpGen Announces Participation at the H.C. Wainwright 24th Annual Global Investment Conference

This in-person and virtual (hybrid) conference to be held September 12-14, 2022 ROCKVILLE, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) — OpGen, Inc. (Nasdaq: OPGN, “OpGen”), today announced it will be featured as a presenting company at the H.C. Wainwright 24th Annual Global Investment Conference. The conference is being held as a hybrid in-person and virtual event on September 12-14, 2022. The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 500 company presentations scheduled as live feed or available on-demand. Oliver Schacht, CEO, and Albert Weber, CFO, will be available for in-person meetings at the conference, and management will provide an overview of the Company’s business during the company’s presentation. Those...

Continue reading

Jushi Holdings Inc. Announces Participation in Upcoming Conferences and Events in September 2022

BOCA RATON, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCQX: JUSHF), a vertically integrated, multi-state cannabis operator, announced that Jushi’s management will participate in the following upcoming conferences and events:Needham’s 3rd Annual Virtual Cannabis Conference is being held on September 7, 2022. Trent Woloveck, Chief Commercial Director, is scheduled to participate in a fireside chat at 8:45 a.m. ET, moderated by Matt McGinley, Senior Research Analyst at Needham. Michael Perlman, EVP of Investor Relations, will host one-on-one investor meetings throughout the conference. To register for the fireside chat, please click here. Benzinga Cannabis Capital Conference is being held from September 13-14, 2022. Olivier Blechner, EVP of Business Development, is scheduled...

Continue reading

CVW Cleantech Welcomes New CEO, Akshay Dubey; Announces Stock Option Grant and Private Placement

CALGARY, Alberta, Sept. 06, 2022 (GLOBE NEWSWIRE) — CVW CleanTech Inc. (the “Company” or “CVW CleanTech”) (TSX-V: CVW) CVW CleanTech Inc. (TSX-V:CVW (the “Company” or “CVW CleanTech”) is pleased to announce the appointment of Akshay Dubey as Chief Executive Officer (“CEO”), effective September 14, 2022. Mr. Dubey will relocate to Calgary from November 1, 2022 and lead the Company into the next phase of its evolution, as it focuses on commercializing its patented oil sands reprocessing technologies and applying a unique financial structure to a rapidly growing clean tech industry. In addition, Mr. Dubey will be appointed to the Board of Directors. Mr. Dubey, previously reported directly to the Board of Directors of BaseCore Metals LP (“BaseCore”) which he led since its inception and was recently sold for...

Continue reading

Tritium Raises a New Capital Package Featuring a $150 Million Debt Facility and a $75 Million Committed Equity Facility

Tritium Overhead Photo Overhead photo of Tritium’s PKM150 fast chargers for electric vehicles.The existing $90 million senior debt facility from Cigna & Barings has been extended by $60 million to a $150 million facility. A committed equity facility for up to $75 million has been established with B. Riley. The net injection of incremental capital of up to $135 million will be used to fund working capital to accelerate production, further product development, and support operations around the world. Despite volatile market conditions, this funding package further demonstrates the strong investor support in the differentiated market position of Tritium and its technology, buoyed by the very strong growth in the electric vehicle (EV) market and expanding government support for the EV sector around the globe.BRISBANE, Australia,...

Continue reading

Context Therapeutics® to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecological cancers, today announced that Chief Executive Officer Martin Lehr will participate in a fireside chat during the H.C. Wainwright 24th Annual Global Investment Conference taking place virtually and in-person September 12-14, 2022, in New York City. The fireside chat will be available on demand for conference participants beginning September 12 at 7 a.m. ET. The Company will be available in-person in New York City to participate in one-on-one meetings in conjunction with the conference. Details about the conference can be found here: https://hcwevents.com/annualconference/. About Context Therapeutics®Context Therapeutics Inc. (Nasdaq:...

Continue reading

BridgeBio Pharma to Participate in September Investor Events

PALO ALTO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that members of the management team will participate in the following upcoming investor conferences: Citi’s 17th Annual BioPharma Conference, Boston, MA: September 7th at 8:50 am ET  Morgan Stanley Global Healthcare Conference, New York, NY: September 13th at 7:20 am ET  Baird Global Healthcare Conference, New York, NY: September 14th at 12:50 pm ET  H.C. Wainwright 24th Annual Global Investment Conference, New York, NY: September 14th at 11:30 am ET Cantor Fitzgerald’s Genetic Medicines Conference, New York, NY: September 15th Jefferies Genetic Cell and Medicine Summit, New York, NY: September 29th Biotech...

Continue reading

Revival Gold Provides Update on Beartrack-Arnett Prefeasibility Study

TORONTO, Sept. 06, 2022 (GLOBE NEWSWIRE) — Revival Gold Inc. (TSXV: RVG, OTCQX: RVLGF) (“Revival Gold” or the “Company”), is pleased to provide an update on the status of work on a Prefeasibility Study (“PFS”) for the Beartrack-Arnett Gold Project (“Beartrack-Arnett”) located in Lemhi County, Idaho, USA. PFS Team and ScheduleRevival Gold has appointed Kappes Cassiday Associates (“KCA”) as the lead PFS consultant focused on metallurgy, infrastructure design and overall study economic analysis with Independent Mining Consultants Inc. (“IMC”) engaged on mineral resources and to develop PFS-level open pit designs and mine plans. KCA and IMC are US-based experts in gold heap leach mine design and operations.Technical studies in support of the PFS (see below) are progressing on track; however, with the shift in overall project management...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.